Novo Nordisk Reports Cardiovascular Outcomes of Oral Semaglutide in PIONEER 6 Study for Type 2 Diabetes
Shots:
- The PIONEER 6 study results involve assessing oral Semaglutide vs PBO in 3-183 patients with type 2 diabetes at high risk of cardiovascular events
- The PIONEER 6 study results: met its 1 EPs i.e non-inferiority for MACE; cardiovascular death events (0.9% vs 1.9%); non-fatal stroke (0.8% vs 1.0%); non-fatal myocardial infarctions (2.3% vs 1.9%); presented at ADA 79th Scientific Sessions and published in NEJM
- Semaglutide is an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of T2D- developed using Novo Nordisk's protein-acylation technology- and is administered using an injection device
Ref: GlobeNewsWire | Image: Bridgetnmiller.Weebly
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com